Trial Profile
A Phase 1b/2, First-in-Human, Dose Escalation and Expansion Study of XMT-1536 In Patients With Solid Tumors Likely to Express NaPi2b
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 17 Nov 2023
Price :
$35
*
At a glance
- Drugs Upifitamab rilsodotin (Primary)
- Indications Adenocarcinoma; Carcinoma; Endometrial cancer; Fallopian tube cancer; Non-small cell lung cancer; Ovarian cancer; Peritoneal cancer; Renal cell carcinoma; Salivary gland cancer; Solid tumours; Thyroid cancer
- Focus Adverse reactions; First in man; Proof of concept; Therapeutic Use
- Sponsors Mersana Therapeutics
- 08 Nov 2023 Planned End Date changed from 31 Dec 2024 to 31 Oct 2024.
- 08 Nov 2023 Status changed from recruiting to active, no longer recruiting.
- 27 Oct 2023 This trial has been completed in Bulgaria, according to the European Clinical Trials Database record.